research Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist
Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
Search
for
Sort by
Research
690-720 / 1000+ results research Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
research Baricitinib in pediatric chronic immune thrombocytopenia and associated autoimmune conditions: a case report
Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
research Formulation Development, Pharmacological Evaluation, and Characterization of Eclipta alba Phytosomes
Eclipta alba phytosomes improve bioavailability and therapeutic effects.
research Disproportionality analysis comparing safety profiles of sonidegib and vismodegib based on the FAERS database
Sonidegib and vismodegib have different side effects and reporting patterns.
research Understanding Eyebrow and Eyelash Involvement in Patients with Alopecia Areata and Responsiveness to Treatment with Baricitinib.
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
research Baricitinib in Alopecia Areata
Baricitinib is not very effective for severe alopecia areata.
research Étude PCPT : les biais attendus et leur gestion
Systematic end-of-trial biopsies are the most reliable way to assess outcomes.
research The management of hirsutism
The document helps doctors recognize and treat excessive hair growth in women.
research Virilizing Ovarian Tumor in a Postmenopausal Women
research A syndromic extreme insulin resistance caused by biallelic POC1A mutations in exon 10
Mutations in the POC1A gene can cause a unique form of extreme insulin resistance and short stature.
research 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.
research Crystal Structure and Synthesis of 17α-Acetoxy-4-bromopregn-4-ene-3,20-dione
The document concludes that a compound with potential for treating prostate cancer and hair loss was successfully made and its detailed structure was confirmed.
research Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials
Ritlecitinib effectively treats alopecia areata with manageable side effects.
research Pharmacologic Modulation of Sebaceous Gland Activity: Mechanisms and Clinical Applications
The document concludes that new treatments are needed to better manage acne and reduce side effects related to current therapies.
research Formulation and evaluation of self-nanoemulsifying drug delivery system for improved oral delivery of exemestane hydrochloride
The new drug delivery system improves exemestane's absorption and effectiveness.
research Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.
research The role of glypican-4, thyroid stimulating hormone, and reproductive hormones in polycystic ovary syndrome progress among Iraqi women
Glypican-4 may help indicate insulin sensitivity and lipid issues in women with PCOS.
research Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials
Baricitinib significantly regrows hair in severe alopecia areata patients.
research Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
research Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome
SHBG may be a useful early indicator and treatment target for PCOS.
research Interventions for Hirsutism
Oral contraceptives help mild hirsutism, while flutamide and spironolactone help severe cases.
research Management of Hirsutism and Acne in Women with Polycystic Ovary Syndrome: A Narrative Review of Current Evidence and Emerging Therapies
Treating hirsutism and acne in women with PCOS needs a personalized approach using oral contraceptives, antiandrogens, and sometimes metformin.
research Chromatographic Method for Simultaneous Quantification of Gemcitabine and Olaparib Recovered from Isolated Pancreatic Tissue
A reliable method was developed to measure gemcitabine and olaparib in pancreatic tissue, aiding pancreatic cancer treatment.
research A Pilot Study of a Grape Seed Procyanidin Extract for Lung Cancer Chemoprevention
Grape seed extract may safely and effectively help prevent lung cancer.
research Therapeutic Response of Alopecia Areata‐Associated Nail Changes to Baricitinib
Baricitinib may effectively treat nail changes in alopecia areata.
research Comparing the Efficacy of Myo-Inositol Plus α-Lactalbumin vs. Myo-Inositol Alone on Reproductive and Metabolic Disturbances of Polycystic Ovary Syndrome
Myo-inositol plus α-lactalbumin works better than myo-inositol alone for improving symptoms of PCOS.
research Management of Alopecia Due to Cancer Therapies
The document concludes that scalp cooling and treatments like minoxidil can help manage hair loss from cancer therapy.
research Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.